

Wednesday Evening 22nd February 2017

IACR Junior Council and Outreach Session (Wednesday Evening)

- 17.00-17.30** **Finger Food Reception/ Meet and greet**
- 17.30-18.30** **Session 1: Careers and Recruitment Session**
(Chaired by Maria Prencipe and Maeve Kiely)
- 17.30** **Ms. Naoimh O'Connor**, (Research Careers Manager, University College Dublin)
'The Post-PhD Job-seeking Strategy'
- 17.45** **Mr. Oisín O'Diomasáigh**
(Graduate Advice Program Manager Life Science Consultants)
'Unravelling your career path- Looking at the Pharma/Biotech sector and using the 5Ws Where/What/Why/When/who.'
- 18.00** **Dr Linda Nolan** (Managing Director MyBio Ltd)
'The transition from Ph.D student to business owner.'
- 18.15-18.30** **Panel Discussion Q&A**
- 18.30-19.30** **Session 2. Grant Writing and Science Communication Session**
(Chaired by Denis Collins and Sara Charmsaz)
- 18.30** **Mr Sean Duke** (Science Journalist, Broadcaster, Author)
'Why Science Communication matters'.
- 18.45** **Prof Chris Scott** (Chair of Pharmaceutical Biosciences), Queens University Belfast
'Conducting commercially relevant research in academia - walking the tightrope'
- 19.00** **Dr Elaine Dunleavy** (SFI-PIYRA Awardee NUI Galway)
'My experience as a SFI-HRB-Wellcome Trust Career Development Fellow'
- 19.15-19.30** **Panel Discussion Q&A**

KINDLY SPONSORED BY:



Thursday 23rd February 2017 - IACR Scientific Sessions

- 09.00 - 09.15: **Welcome Address: Prof William Watson (IACR President)**
- 09.15 -10.15: **PROFFERED PAPER 1 SESSION (selected from Abstract Submissions)**
(Chaired by Dr Eva Szegezdi and Marion Butler)
4 x 15 minute presentations (12 mins + 3 mins Q&A)
- 09.15-09.30 **IDENTIFICATION AND CHARACTERISATION OF NOVEL RACK1 BINDING PARTNERS THAT MAY MODULATE THE ELONGATION PHASE OF PROTEIN SYNTHESIS.**
Beatrice Malacrida^{1,2}, RK Flygaard³, CM Dowling^{1,2}, JC Coffey¹, LB Jenner³, PA Kiely^{1,2},
¹Graduate Entry Medical School, University of Limerick, ²Health Research Institute , University of Limerick, ³Department of Molecular Biology and Genetics, Aarhus University, Aarhus
- 09.30-09.45 **FKBPL AS A NOVEL PROGNOSTIC BIOMARKER AND THERAPEUTIC AGENT IN HIGH GRADE SEROUS OVARIAN CANCER**
Stephanie L Annett^{1,2}, L McClement¹, HO McCarthy¹, F Furlong¹, I Harley³, G McCluggage³, T Robson^{1,2},
¹Molecular and Cellular Therapeutics , Royal College of Surgeons, Dublin
²School of Pharmacy, Queen's University Belfast, ³, Belfast Health of Social Care Trust, Belfast
- 09.45-10.00 **IDENTIFICATION OF SPLICEOSOMAL COMPONENTS AS NOVEL THERAPEUTIC TARGETS FOR THE THERAPY OF CHILDREN WITH HIGH-RISK MYCN-AMPLIFIED NEUROBLASTOMA**
Melinda Halasz^{1,2}, T Santra¹, S Furney³, D Fey¹, K Iljin⁴, M Fischer⁵, F Westermann⁶, AT Look⁷, W Kolch^{1,2,3}
¹Systems Biology Ireland, University College Dublin, ²School of Medicine, University College Dublin, ³Conway Institute, University College Dublin, ⁴, VTT Technical Research Centre of Finland, Espoo, ⁵Department of Paediatric Haematology and Oncology , University Hospital Cologne, Cologne, ⁶German Cancer Research Centre, Heidelberg, ⁷Dana-Farber Cancer Institute, Boston
- 10.00-10.15 **STROMAL CELL IMMUNOMODULATORY POTENTIAL IN THE TUMOUR MICROENVIRONMENT IS REGULATED BY INFLAMMATORY SIGNALLING**
Grace O'Malley^{1,2}, SD Naicker², K Lynch², P Lohan², A Rigalou^{1,2}, T Ritter², LJ Egan¹, AE Ryan^{1,2}
¹Pharmacology and Therapeutics, NUI Galway, Galway
²Regenerative Medicine Institute (REMEDI), College of Medicine, NUI Galway, Galway
- 10.15-10.30: **Gold Sponsor Presentation – Pfizer**
“Development of an anti-P-cadherin/ anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer”
Brian Fennell - BioMedicine Design (BMD), Pfizer
- 10.30-11.00: **TEA/COFFEE/POSTERS & MEET THE SPONSORS**

- 11.00-12.30: **PLENARY SESSION 1: TARGETING TRANSCRIPTIONAL DE-REGULATION IN CANCER**
(Chaired by Dr Triona NiChonghaile and Dr Simon McDade)
- 11.00-11.30 **‘DRIVERS’ AND ‘FEEDBACK LOOPS’ IN PROSTATE CANCER CELLS**
Dr Ian Mills, Reader, Queens University Belfast
- 11.30-12.00 **THE IMPACT OF CELLULAR AGE ON LEUKAEMIC TRANSFORMATION**
Dr Karen Keeshan, Reader, Paul O’Gorman Leukaemia Research Centre
College of Medicine, Veterinary & Life Sciences
(University of Glasgow)
- 12.00-12.30 **ACQUIRED CYP19A1 AMPLIFICATION IS AN EARLY SPECIFIC MECHANISM OF
AROMATASE INHIBITOR RESISTANCE IN ERA METASTATIC BREAST CANCER**
Dr Luca Magnani, Imperial College London
- 12.30-13.00 **‘SATELLITE SESSION’ WITH NEXCELOM (Main Auditorium)**
*“A Rapid High-Throughput 3D Tumor Spheroid Imaging Cytometry Screening
Method for Drug Discovery”*
Scott Cribbes, Director of Applications and Emerging Technologies, Nexcelom
- 13.00-14.00 **LUNCH, TRADE EXHIBITION AND POSTER VIEWING**
IACR JUNIOR COUNCIL NETWORKING LUNCH
- 14.00-16.00: **PLENARY SESSION 2: CHALLENGES IN CHILDHOOD CANCERS**
(Chaired by Dr Olga Piskarvea and Dr Graham Pidgeon)
- 14.00-14.30 **ORIGIN, EVOLUTION AND TARGETING OF CHILDHOOD LEUKAEMIA**
Professor Tariq Enver, UCL Cancer Institute, London
- 14.30-15.00 **THE PROMISE AND CHALLENGE OF NUCLEIC ACIDS AS CIRCULATING BIOMARKERS
FOR RISK STRATIFICATION AND ADAPTIVE CANCER TREATMENT IN CHILDREN
WITH NEUROBLASTOMA**
Professor Sue Burchill, Leeds Institute of Cancer and Pathology, UK.
- 15.00-15.30 **IMPACT OF TRISOMY 21 ON HAEMATOPOIESIS AND LEUKAEMIA IN EARLY LIFE**
Professor Irene Roberts, Department of Paediatrics and MRC Molecular
Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford,
UK
- 15.30-16.00 **MODULATING THE NEUROBLASTOMA PHENOTYPE WITH EPIGENETICALLY
REGULATED microRNA**
Prof. Raymond Stallings, Director of Research & Innovation, RCSI Office of Research
and Innovation Royal College of Surgeons in Ireland
- 16.00-16.40: **ORAL POSTER PRESENTATIONS (Prof. John Fitzpatrick Medal)**
(Chaired by Dr Antoinette Perry and Dr Mark Tangney)
(6 x 6 minute presentations, selected from Abstract Submissions)
- 16.00-16.06 **PRIMARY CULTURES OF PANCREATIC CANCER PATIENT DERIVED XENOGRAPTS TO
MODEL CHEMOTHERAPEUTIC RESPONSE**
Sandra Roche¹, V Guinot¹, F O’Neill¹, N Swan², N Lopez-Straubinger³, J Murphy², K
Conlon², J Geoghegan², R McDermott², J Meiller¹, R O’Connor¹, M Moriarty^{1,2}, M
Clynes¹, RM Staubinger³, N Barron¹
¹National Institute for Cellular Biotechnology, Dublin City University, Dublin 9
², St Vincent’s University Hospital, Dublin 4
³Department of Pharmaceutical Sciences, , University at Buffalo, State University of
New York, Buffalo, New York

- 16.06-16.12 **THE AMP-KINASE PROTEIN AS A POTENTIAL THERAPEUTIC TARGET IN COLORECTAL CANCER**
Ciara C Dunphy^{1,2}, A O' Brien^{1,2}, H Dussmann^{1,2}, J Lopez³, S Tait³, SL Pfeiffer^{1,2}, JHM Prehn^{1,2,1}
¹Centre for Systems Medicine, Royal College of Surgeons Ireland, Dublin
²Physiology and Medical Physics, University of Glasgow, Glasgow
³The Beatson Institute for Cancer Research, University of Glasgow, Glasgow
- 16.12-16.18 **TACKLING ACQUIRED RESISTANCE MECHANISMS IN MALIGNANT MELANOMA**
C Fitzgibbon¹, E Chiquero-Leon¹, Z Liu¹, N Rauch¹, E Panada¹, A von Kriegsheim¹, W Kolch^{1,2}, **Jens Rauch**
¹Systems Biology Ireland, University College Dublin, ²Conway Institute, University College Dublin, Dublin
- 16.18-16.24 **CONTRIBUTION OF IRE1 SIGNALING TO THE PROGRESSION OF TRIPLE NEGATIVE BREAST CANCER**
Susan E Logue¹, P Cleary¹, E McGrath¹, K Mnich¹, A Samali¹
¹Apoptosis Research Centre, School of Natural Sciences, National University of Ireland Galway, Galway
- 16.24-16.30 **NOVEL SDC2-FC PEPTIDES ATTENUATE TGFB, CXCR4 AND PD-L1 SIGNALLING IN BREAST CANCER STROMA.**
Paul Loftus¹, L Watson¹, L Deedigan¹, L O'Flynn¹, M Kerin², T O'Brien³, S Elliman¹, LR Barkley⁴
¹Orbsen Therapeutics, National University of Ireland, ²Lambe Institute, National University of Ireland, ³REMEDl, National University of Ireland, ⁴National University of Ireland, Galway
- 16.30-16.36 **EMPLOYING MESENCHYMAL STEM CELLS AS TUMOUR-TARGETED DELIVERY VEHICLES OF EXOSOMAL microRNA-379**
Killian P O'Brien¹, K Gilligan¹, S Khan¹, B Moloney¹, K Thompson², P Lalor², P Dockery², H Ingoldsby³, MJ Kerin¹, RM Dwyer¹
¹Discipline of Surgery, School of Medicine, National University of Ireland, Galway, ²Discipline of Anatomy, School of Medicine, National University of Ireland, Galway, ³Discipline of Pathology, School of Medicine, National University of Ireland, Galway, Galway
- 16.40-16.55: **Gold Sponsor Presentation – Nanostring**
3D Biology Technology: DNA, RNA and Protein
Ajay Johni, Nanostring Technologies
- 16.55- 17.30: **TEA/COFFEE/POSTERS & MEET THE SPONSORS**
- 17.30-18.30: **IRISH CANCER SOCIETY SCHOLAR AND FELLOW PRESENTATIONS**
(The highest scoring abstracts from 2 x ICS funded PhD students and 2 x ICS funded Postdocs will be selected for presentation)
(Chairs: Dr Naomi Walsh and Dr Isabella Bray)
- 17.30-17.45 **RNA SEQUENCING IDENTIFIES BROMODOMAIN PROTEINS AS A THERAPEUTIC STRATEGY FOR INVASIVE LOBULAR CARCINOMA (PhD)**
Louise Walsh¹, B Moran², S Das¹, F Tarrant², Y Fan², P Schouten³, S Chin⁴, S Linn³, R Bernards⁵, C Caldas⁴, WM Gallagher², T Ní Chonghaile*⁶, DP O'Connor*¹
¹Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, ²School of Biomolecular and Biomedical Science, University College Dublin, ³Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, ⁴Cancer Research UK Cambridge institute, University of Cambridge, Cambridge, ⁵Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, ⁶Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin

- 17.45-18.00
(PhD) **EXPRESSION OF THE COCAINE- AND AMPHETAMINE-REGULATED TRANSCRIPT (CART) RECRUITS BAF CHROMATIN REMODELLING COMPLEXES TO THE ESTROGEN RECEPTOR**
Brian P Mooney¹, S Das¹, R Klinger², B Moran², E Conway³, B Doyle², K Wynne², WM Gallagher², T Ni Chonghaile⁴, G Cagney², AP Bracken³, DP O'Connor¹
¹Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin
²School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Dublin, ³Smurfit Institute of Genetics, Trinity College Dublin, Dublin
⁴Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin
- 18.00-18.15
(Postdoc) **AROMATASE INHIBITOR REPURPOSING FOR THE TREATMENT OF AN AGGRESSIVE BRAIN CANCER, GLIOBLASTOMA, USING ANTI-GD2-CH14.18/CHO COATED BIODEGRADABLE NANOPARTICLES.**
Amanda Tivnan¹, H Heilinger^{1,2}, JM Ramsey³, G O'Connor³, JL Pokorny^{4,5}, JN Sarkaria⁵, BW Stringer⁶, BW Day⁶, Boyd AW⁶, EL Kim⁷, HN Lode⁸, SA Cryan³, JHM Prehn¹
¹Centre for Systems Medicine, Department of Physiology and Medical Physics, The Royal College of Surgeons in Ireland, Dublin, ²IMC Fachhochschule Krems, University of Applied Sciences, Krems, Austria, ³School of Pharmacy & Tissue Engineering Research Group, Dept Anatomy, RCSI & Centre for Research in Medical Devices (CURAM), NUIG., Dublin, ⁴Dept of Radiation, Mayo Clinic, Rochester, MN, ⁵Centre for Mind and Brain, University of California, Davis, California, ⁶Brain Cancer Research Unit, QIMR Berghofer Medical Research Institute, Brisbane, ⁷Department of Neurooncology, Johannes Gutenberg University Medical Center, Mainz, Germany, ⁸Department of Paediatrics and Paediatric Haematology/Oncology, University of Greifswald, Greifswald, Germany
- 18.15-18.30
(Postdoc) **MECHANISTIC INTERROGATION OF PRE-TREATMENT LOW DOSE ASPIRIN EFFECTS IN HER 2 POSITIVE BREAST CANCER**
Ian S Miller¹, S Khan², S Das³, LP Shiels⁴, B Moran⁴, FP Leacy⁵, PL Loadman⁶, RS Kerbel⁵, D O'Connor³, K Bennett⁸, RM Dywer², AT Byrne¹
¹Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin ² Department of Surgery and REMEDI, National University of Ireland, Galway, Galway ³Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, ⁴Conway Institute of Biomedical and Biomolecular Science, University College Dublin, Dublin, ⁵Biostatistics Core, Royal College of Surgeons in Ireland, ⁶Department of Chemistry, University of Bradford, Bradford, UK, ⁷Sunnybrook Institute, University of Toronto, Toronto, Canada, ⁸Dept of Population and Health Science , Royal College of Surgeons in Ireland, Dublin
- 18.30-18.45: **Short address from Dr Robert O'Connor (The Irish Cancer Society)**
- 18.45-19.45: **IRISH CANCER SOCIETY LECTURE**
“DELIVERING PRECISION MEDICINE FOR MELANOMA”
Professor Richard Marais, Director
Cancer Research UK Manchester Institute
- 19.45–22.30: **FORMAL POSTER SESSION**
19.45-20.30: Buffet Dinner and Wine Reception
20.30-21.30: TRADE EXHIBITION/ /Presentation of odd Poster Numbers
21.30-22.30: TRADE EXHIBITION/ **Coffee and Dessert**/Presentation of even Poster Numbers

Friday 24th February 2017 - IACR Scientific Sessions

- 08.00-09.00: **Junior Council Networking Breakfast**
- 09.00-10.30: **PLENARY SESSION 3: “TRANSLATING QUESTIONS INTO TREATMENTS FOR PATIENTS”**
(Chaired by Professor William Watson and Dr Norma O’Donovan)
- 09.00-09.15 **“NEW USES FOR AN OLD DRUG IN MULTIPLE MYELOMA”**
Janusz Krawczyk, Senior Lecturer in Haematology and Cellular Therapy, Blood Cancer Network, Galway
- 09.15-09.20 **Questions**
- 09.20-09.35 **TCHL: A PHASE II NEO-ADJUVANT STUDY ASSESSING DUAL OVER SINGLE HER2 BLOCKADE WITH TRASTUZUMAB AND LAPATINIB IN COMBINATION WITH DOCETAXEL AND CARBOPLATIN IN HER2 POSITIVE BREAST CANCER PATIENTS**
Giuseppe Gullo, Consultant Medical Oncologist, St. Vincent’s University Hospital, Dublin
- 09.35-09.50 **‘IDENTIFYING EARLY PROGNOSTIC MARKERS OF PATHOLOGICAL COMPLETE RESPONSE (PCR) IN NEOADJUVANT TCHL TREATED HER2-POSITIVE BREAST CANCER AND STUDYING THE IMPACT OF TCHL BASED THERAPY ON THE MOLECULAR EVOLUTION OF HER2-POSITIVE BREAST CANCER.’**
Alex Eustace PhD, HRB Post-Doctoral Researcher, RCSI PGHPE 1
Royal College of Surgeons in Ireland, RCSI Education & Research Centre, Beaumont Hospital, Beaumont, Dublin 9
- 09.50-09.55 **Joint Questions**
- 09.55-10.25 **“CREATING AN ABCOPAL EFFECT: FROM OBSERVATION TO DESIGN”**
Declan Soden, Lead Investigator, Cork Cancer Research Centre (CCRC), University College Cork
Derek Power, Consultant Medical Oncologist, Dept of Medical Oncology, Cork University Hospital, Cork
- 10.25-10.30 **Joint Questions**
- 10.30-10.45: **Gold Sponsor Presentation – Philips Digital Pathology Solutions**
Integrating Computational Pathology and Tissue Analytics for Molecular Pathology
Eileen Regan, (Key Account Manager, Philips Digital Pathology Solutions, Royal Philips)
- 10.45-11.15: **TEA/COFFEE/POSTERS & MEET THE SPONSORS**
- 11.15-11.30: **CANCER RESEARCH TO IMPACT CANCER CARE**
Orla Dolan, Head of Fundraising
Breakthrough Cancer Research

- 11.30-12.30: **PROFFERED PAPER 2 SESSION**
4 x 15 minute presentations (12 mins + 3 mins Q&A)
(Chaired by Dr Niamh Buckley and Dr Tara Dalton)
- 11.30-11.45 **HIGH CDK7 IS LINKED TO POOR OUTCOME IN TRIPLE-NEGATIVE BREAST CANCER AND IS A RATIONAL THERAPEUTIC TARGET**
B Li¹, T Ni Chonghaile², Y Fan¹, SF Madden³, R Kinger¹, AE O'Connor¹, G O'Hurley⁴, GM Udipi⁴, J Joseph⁴, F Tarrant¹, E Conroy¹, A Gaber⁵, SF Chin⁶, HA Bardwell⁶, E Provenzano⁷, T Dubois⁸, S Linn⁹, C Caldas⁶, DP O'Connor¹⁰, WM Gallagher^{1,4}
¹School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, ²Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland, Dublin, ³Population Health Sciences Division, Royal College of Surgeons in Ireland, Dublin, ⁴OncoMark Ltd, Belfield Innovation Park, Dublin ⁵Faculty of Medicine, Lund University, Lund, ⁶Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, ⁷Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, ⁸Department of Translational Research, Breast Cancer Biology Group, Institut Curie, Paris, ⁹Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, ¹⁰Department of Molecular & Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, ¹⁹Department of Molecular & Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin
- 11.45-12.00 **A HIGH-THROUGHPUT SCREEN IDENTIFIED CANCER SELECTIVE SMALL MOLECULES THAT KILL INDEPENDENT OF MITOCHONDRIAL APOPTOSIS**
Catriona M Dowling¹, M Hemann², J Bradner³, A Letai⁴, T Ni Chonghaile¹
¹Department of Physiology and Medical Physics, Royal College of Surgeons, Dublin
²Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, ³Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, ⁴Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
- 12.00-12.15 **CancerGD: A RESOURCE FOR IDENTIFYING AND INTERPRETING GENETIC DEPENDENCIES IN CANCER**
S Bridgett¹, J Campbell², C.J. Lord², Colm J. Ryan¹
¹Systems Biology Ireland, University College Dublin, ² The CRUK Gene Function Laboratory, The Institute of Cancer Research, London, ³Helen Diller Family Comprehensive Cancer Centre, University of California, San Francisco, San Francisco
- 12.15-12.30 **A NOVEL ROLE FOR THE COMPLEMENT SYSTEM IN RADIORESISTANT OESOPHAGEAL ADENOCARCINO**
Niamh Lynam-Lennon¹, D Lavin¹, R Byrne¹, JV Reynolds¹, J O'Sullivan¹
¹Department of Surgery, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin
- 12.30-12.45 **Gold Sponsor Presentation – Agilent Technologies**
Providing Future Solutions For Cellular Bioenergetics And Metabolomics Studies
Alex Liversage, Agilent Technologies
- 12.45-13.05 **IACR AGM – All Members Welcome**
- 13.05-14.05: **Lunch, Trade Exhibitions and Poster viewing**

- 14.05-15.35: **PLENARY SESSION 4: ADVANCED MOUSE MODELS IN CANCER**
(Chaired by Dr Brona Murphy and Dr Ken Nally)
- 14.05-14.35 **INTERROGATING OPEN ISSUES IN CANCER PRECISION MEDICINE USING PATIENT-DERIVED XENOGRAFTS**
Dr Annette Byrne, Snr Lecturer, Academic Director for Curriculum Mapping, Royal College of Surgeons in Ireland
- 14.35-15.05 **CANCER EVOLUTION AS A THERAPEUTIC TARGET**
Professor Alberto Bardelli, Dept. of Oncology, University of Torino, Director of the Laboratory of Molecular Oncology and Deputy Director of the Candiolo Cancer Institute-IRCCS, Torino, Italy.
- 15.05-15.35 **PATIENT-DERIVED XENOGRAFTS EFFECTIVELY CAPTURE RESPONSES TO ONCOLOGY THERAPY IN PATIENTS WITH SOLID TUMORS**
David Sidransky MD, Johns Hopkins University, Baltimore, MD 21215
- 15.35-16.00: **Tea/Coffee/Posters & Meet the Sponsors**
- 16.00-17.00: **EACR YOUNG SCIENTIST AWARDS**
(2 x 25 mins + 5 mins Q&A)
Chairs: Professor Alberto Bardelli (President Elect of the EACR) and Professor Amanda McCann (President Elect of the IACR)
- 16.00-16.30 **SERUM RESPONSE FACTOR AS A NOVEL TARGETED THERAPY FOR CASTRATE-RESISTANT PROSTATE CANCER**
Maria Prencipe¹, A O'Neill¹, G O'Hurley², A Fabre³, WM Gallagher⁴, Colm Morrissey⁵, E Kay⁶, W Watson¹
¹UCD School of Medicine, Conway Institute of Biomolecula, University College Dublin, Dublin, ²OncoMark Limited, Nova UCD, Dublin, ³Department of Pathology, St Vincent's University Hospital, Dublin, ⁴UCD School of Biomolecular and Biomedical Science, Conway Institute of Biom, University College Dublin, Dublin, ⁵Department of Urology, University of Washington, Seattle, Washington, ⁶Department of Pathology, RCSI Education and Research Centre, Dublin
- 16.30-17.00 **TRANSLATING NextGen SEQUENCING TO THE CLINIC: TARGETING ACTIONABLE GENES ENRICHED IN BREAST CANCER BRAIN METASTASES**
Damir Vareslija¹, A Fagan¹, N Priedigkeit⁵, E Ward¹, S Purcell¹, L Hudson¹, P O'Halloran³, R Dwyer⁴, M Kerin⁴, P Buckley², M Farrell², S Das⁶, D O'Connor⁶, ADK Hill¹, S Oesterreich⁵, AV Lee⁵, L Young¹
¹Surgery Department, RCSI, Dublin, ²Neuropathology, Beaumont, Dublin, ³Neurosurgery, Beaumont, Dublin, ⁴Clinical Science Institute, NUIG, Galway, ⁵Magee-Women's Research Institute, University of Pittsburgh Cancer Institute, Pittsburgh, ⁶MCT, RCSI, Dublin
- 17.00-18.00: **Special IACR Cancer Researcher Medal Presentation:**
Chair: Professor William Watson
2017 Awardee: Professor William Gallagher
"CANCER (RESEARCH) IN IRELAND: PAST, PRESENT AND FUTURE"
Professor William Gallagher, Director of the UCD Conway Institute Professor of Cancer Biology, UCD School of Biomolecular & Biomedical Science, Director of the Irish Cancer Society Collaborative Cancer Research Centre BREAST-PREDICT
- 18.00 **CLOSE OF MEETING**
- 19.00 **GALA DINNER IN KILKENNY CASTLE - AWARDS/PRESENTATIONS**
(Transportation has been arranged – Bus Departs Hotel at 18.45)